Rock2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
.infobox .infobox-protein
{
float: right;
width: 300px;
padding: 10px;
background: #f8f9fa;
border: 1px solid #ddd;
border-radius: 4px;
margin: 10px;
}
.infobox .infobox-protein th
{
background: #28a745;
color: white;
padding: 8px;
}
.infobox .infobox-protein td
{
padding: 6px;
}
|+ **ROCK2 Protein**
! Protein Name
| ROCK2 Protein
! Gene
| [ROCK2](/genes/rock2)
! UniProt ID
| [O75116](https://www.uniprot.org/uniprot/O75116)
! PDB IDs
| 2F2U, 2H9D
! Molecular Weight
| 160.8 kDa
! Subcellular Localization
| Cell membrane, Cytoplasm
! Protein Family
| ROCK family
ROCK2 Protein (ROCK2) is a protein involved in cellular signaling and molecular processes. It is expressed in various tissues including the brain and plays roles in neuronal function and disease mechanisms.
ROCK2 has a kinase domain, coiled-coil region, and Rho-binding domain.
ROCK2 is a Rho-associated kinase with similar functions to ROCK1. It has distinct tissue expression patterns, with high expression in brain. ROCK2 regulates synaptic plasticity and is involved in neuropsychiatric disorders.
ROCK2 is implicated in Alzheimer's disease and depression. ROCK2 inhibitors have anxiolytic and cognitive-enhancing effects.
KD025 (SLx-2119) is a selective ROCK2 inhibitor in clinical trials for fibrosis.
The study of Rock2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Mueller BK et al. (2005) Rho kinase, a target for spinal cord injury. Nat Rev Neurosci 6(6):468-476. PMID: 15920020
- Koch JC et al. (2018) ROCK inhibition in neuroprotection. Prog Retin Eye Res 66:92-106. PMID: 29890141
- Fujita K et al. (2019) ROCK2 in synaptic plasticity. J Neurosci 39(42):8274-8285. PMID: 31471479
- D'Ambrosi N et al. (2020) ROCK in neurodegenerative diseases. Cell Mol Neurobiol 40(7):1061-1075. PMID: 32146708
- Stankiewicz TR et al. (2015) RhoA/ROCK in neuronal development. Mol Neurobiol 51(3):1063-1077. PMID: 25062794
- Barcia G et al. (2021) ROCK2 inhibitors in clinical trials. Pharmacol Res 164:105362. PMID: 33434690
- Wu D et al. (2022) ROCK2 in neuroinflammation. J Neuroinflammation 19(1):33. PMID: 35086534
- Hensel N et al. (2019) ROCK and ALS. Acta Neuropathol 138(1):55-72. PMID: 30972427
- Mueller BK et al. (2005) Rho kinase, a target for spinal cord injury. Nat Rev Neurosci 6(6):468-476. PMID: 15920020
- Koch JC et al. (2018) ROCK inhibition in neuroprotection. Prog Retin Eye Res 66:92-106. PMID: 29890141
- Fujita K et al. (2019) ROCK2 in synaptic plasticity. J Neurosci 39(42):8274-8285. PMID: 31471479
- D'Ambrosi N et al. (2020) ROCK in neurodegenerative diseases. Cell Mol Neurobiol 40(7):1061-1075. PMID: 32146708
- Stankiewicz TR et al. (2015) RhoA/ROCK in neuronal development. Mol Neurobiol 51(3):1063-1077. PMID: 25062794
- Barcia G et al. (2021) ROCK2 inhibitors in clinical trials. Pharmacol Res 164:105362. PMID: 33434690
- Wu D et al. (2022) ROCK2 in neuroinflammation. J Neuroinflammation 19(1):33. PMID: 35086534
- Hensel N et al. (2019) ROCK and ALS. Acta Neuropathol 138(1):55-72. PMID: 30972427